Lundbeck Q3 2019 Financial Results

9M 2019 highlights: Continued strong performance of strategic brands and executing on our Expand and Invest to Grow strategy 4 +29% Strategic Brands +24% in local currencies • Strategic brands constitute 53% of revenue +8% International Markets Strategic brands grew 38% and constitute 18% of revenue Strong demand in general +7% Europe Strategic brands grew 27% and constitute 51% of revenue Strong demand in general • . Expand and Invest to Grow • Acquisition of Alder Transaction completed on 22 Oct. Eptinezumab submitted in the U.S. PDUFA action date: 21 Feb. 2020 Pipeline expansion • . Eptinuzumab (LCM) Phase III: Brexpiprazole PTSD Phase II: Brexpiprazole BPD Three projects enter phase I Solid cash position • Net cash Net cash 9M. 19: DKK 4,024m Net debt FY2019e: DKK -7bn following closure of Alder transaction Lundbeck

View entire presentation